WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells

International Journal of Cancer

Volumn 109, Issue 3, 2004, Pages 385-392

  Koesters, Robert ^a   Linnebacher, Michael ^a   Coy, Johannes F ^b   Germann, Anja ^a   Schwitalle, Yvette ^a   Findeisen, Peter ^a   Doeberitz, Magnus Von Knebel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MTM Laboratories AG   (Germany)

Author keywords

Gene expression; Mutations; Peptides; WT1; Zinc finger region

Indexed keywords

HLA A2 ANTIGEN; ISOPROTEIN; MESSENGER RNA; PEPTIDE; TUMOR ANTIGEN; WT1 PROTEIN; ZINC FINGER PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL LEVEL; COLON CANCER; COLON CARCINOMA; COLON MUCOSA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR RECOGNITION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; WILD TYPE;

ANTIGENS, CD40; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CELL DEATH; CHROMIUM; COLON; COLONIC NEOPLASMS; EPITOPES; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 1342309586     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11721     Document Type: Article

References (55)

1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990;343:774-8.
3. Bonetta L, Kuehn SE, Huang A, Law DJ, Kalikin LM, Koi M, Reeve AE, Brownstein BH, Yeger H, Williams BR. Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts. Science 1990;250:994-7.
4. Hosono S, Gross I, English MA, Hajra KM, Fearon ER, Licht JD. E-cadherin is a WT1 target gene. J Biol Chem 2000;275:10943-53.
5. Nichols KE, Re GG, Yan YX, Garvin AJ, Haber DA. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res 1995;55:4540-3.
6. Wemer H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ III, Sens DA, Garvin AJ, LeRoith D, Roberts CT Jr. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 1993;90:5828-32.
7. Wang ZY, Madden SL, Deuel TF, Rauscher FJ III. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992;267:21999-2002.
8. Cook DM, Hinkes MT, Bernfield M, Rauscher FJ III. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 1996;13:1789-99.
9. Kim J, Prawitt D, Bardeesy N, Torban E, Vicaner C, Goodyer P, Zabel B, Pelletier J. The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol 1999;19:2289-99.
10. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 1999;98:663-73.
11. Little MH, Prosser J, Condie A, Smith PJ, van Heyningen V, Hastie ND. Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA 1992;89:4791-5.
12. Varanasi R, Bardeesy N, Ghahremani M, Petruzzi MJ, Nowak N, Adam MA, Grundy P, Shows TB, Pelletier J. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci USA 1994;91:3554-8.
13. Gessler M, Konig A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F. Infrequent mutation of the WT1 gene in 77 Wilms' tumors. Hum Mutat 1994;3:212-22.
14. Koesters R, Adams V, Hassam S, Schaefer R, Schmid M, Moos R, Briner J. Mutational analysis of the tumor suppressor gene WT1: detection of a novel homozygous point mutation in sporadic unilateral Wilms tumor. Int J Oncol 1995;7:1103-7.
15. Ton CC, Huff V, Call KM, Cohn S, Strong LC, Housman DE, Saunders GF. Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus. Genomics 1991;10:293-7.
16. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-9.
17. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-7.
18. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405-12.
19. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-25.
20. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D, Sukumar S. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001;61:921-5.
21. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, Sugiyama H, Noguchi S. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167-71.
22. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, Yao M, Takahashi E, Nakano Y, Hirabayashi H, Shintani Y, Oka Y, et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002;100:297-303.
23. Dennis SL, Manji SS, Carrington DP, Scarcella DL, Ashley DM, Smith PJ, Algar E. M. Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors. Int J Cancer 2002;97:713-5.
24. Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D, Pelletier J. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993;11:393-9.
25. Viel A, Giannini F, Capozzi E, Canzonieri V, Scarabelli C, Gloghini A, Boiocchi M. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. Int J Cancer 1994;57:515-21, 1994.
26. Rodeck U, Bossler A, Kari C, Humphreys CW, Gyorfi T, Maurer J, Thiel E, Menssen HD. Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994;59:78-82.
27. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996;87:2878-84.
28. Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM. Down-regulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 2002;295:784-90.
29. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, Kishimoto T, Sugiyama H. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90:194-204.
30. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000;51:99-107.
31. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95:2198-203.
32. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93.
33. Makita M, Hiraki A, Azuma T, Tsuboi A, Oka Y, Sugiyama H, Fujita S, Tanimoto M, Harada M, Yasukawa M. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002;8:2626-31.
34. Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M. Identification of a HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT-gene. J Clin Immunol, 2003;23:415-23.
35. Van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996;156:3308-14.
36. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 2001;93:6-11.
37. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
38. Brossart P, Bevan MJ. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med 1996;183:2449-58.
39. Houbiers JG, Nijman HW, Van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-7.
40. Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000;12:107-17.
41. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-50.
42. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-82.
43. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
44. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96:1480-9.
45. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-7.
46. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997;25:945-50.
47. Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997;90:4230-2.
48. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
49. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr., Daniel CW. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997;94:8132-7.
50. Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S, Oka Y, Oji Y, Tatekawa T, Tsuboi A, Tagawa S, Kitani T, et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 1996;88:4396-8.
51. Menssen HD, Bertelmann E, Bartelt S, Schmidt RA, Pecher G, Schramm K, Thiel E. Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 2000;126:226-32.
52. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T, Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000;164:1873-80.
53. Knights AJ, Zaniou A, Rees RC, Pawelec G, Muller L. Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 2002;51:271-81.
54. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000;20:195-202.
55. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.